EXHIBIT 99

                                              [ThermoGenesis Corp. Logo omitted]


                   THERMOGENESIS CORP. RETAINS MATTHEW PLAVAN,
                           NEW CHIEF FINANCIAL OFFICER

RANCHO CORDOVA,  California (May 5, 2005) -- THERMOGENESIS CORP. (Nasdaq:  KOOL)
today  announced that Mr. Matthew Plavan has been appointed as the Company's new
Chief  Financial  Officer,  reporting  directly to Kevin Simpson,  the Company's
President and Chief Operating  Officer.  Mr. Plavan succeeds Mrs. Renee Ruecker,
who sought reduced working hours for family reasons and who will become Director
of SEC  Reporting,  a new position  created to  accommodate  the Sarbanes  Oxley
compliance requirements.

     Mr. Plavan comes to  ThermoGenesis  from his most recent  position as Chief
Financial Officer of StrionAir,  Inc., an air purification  product  development
and marketing  company where he was instrumental in supporting the launch of the
company by raising $16 million of private equity financing as well as helping to
position its technology to become the new standard in high-efficiency commercial
air filtration.

     Previously,  Mr. Plavan  served in key  financial and operating  leadership
roles within McKesson and McKesson-acquired  companies,  including most recently
the Vice President of Finance for a $300 million division, iMcKesson. Mr. Plavan
gained  valuable  general  management  experience  spearheading  the turn-around
effort which  repositioned the Company's  Disease State Management  division for
substantial year-over-year revenue growth and profitability.  For three years as
the  Senior  Director  of  Investor   Relations  and   International   Corporate
Development at Access Health,  Inc. (before being acquired by McKesson in 1998),
Mr. Plavan oversaw the day-to-day investor relations affairs and reporting while
growing the  Company's  sell-side  research  coverage from three to over a dozen
top-tier  investment bank research  analysts and played a key role in supporting
the due  diligence  for three  acquisitions  ranging  from $130  million to $1.1
billion.

     Mr. Plavan, who grew up in Sacramento,  began his career with Ernst & Young
LLP, where he was an audit manager in the  high-technology  practice  overseeing
audits and  providing  accounting  consulting  services for a number of publicly
held audit clients. Mr. Plavan has been a California CPA since 1992.

     Mr.  Simpson  announced  "We are very  excited to have Matt on board and to
leverage his 17 years of financial,  accounting and operations  experience  from
various healthcare and manufacturing  companies."  Simpson noted that, "Matt has
performed  with  excellence in a number of key executive  roles within  industry
relevant  companies such as McKesson  Health  Solutions and has gained  valuable
leadership  experience  with these  companies  during periods of exceptional and
sustained growth."

     Mr.  Simpson  further  commented, "We would  like to thank  Renee  for her
tireless dedication and exceptional service as Vice President,  Finance and then
CFO over these past 8 years.  We are  fortunate  that Renee will be staying with
the  Company to become the  Director  of SEC  Reporting,  a position  created to
assist  the  Company  with  adhering  to the  recently  imposed  Sarbanes  Oxley
reporting requirements."






About THERMOGENESIS CORP.
-------------------------
THERMOGENESIS CORP. is a leader in enabling  technologies for cell therapeutics.
The Company's  technology  platforms  lead the world in their ability to produce
biological  products from single units of blood.  Umbilical cord blood banks are
utilizing the Company's  BioArchive(R)  System as a critical enabling technology
for cryogenic  archiving of stem cells for transplant,  while its CryoSeal(R) FS
System is used to prepare  hemostatic  and adhesive  surgical  sealants from the
patient's  blood  in  about  an hour.  THERMOGENESIS  CORP.  has been a  leading
supplier of  state-of-the-art  Ultra-Rapid  Blood Plasma Freezers and Thawers to
hospitals and blood banks since 1992.

The  statements  contained in this release  which are not  historical  facts are
forward-looking  statements  that are  subject to risks and  uncertainties  that
could cause  actual  results to differ  materially  from those  expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company's  control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the  Company's  filings  with the  Securities  and Exchange
Commission.

                         For More Information, Contact:

                               THERMOGENESIS CORP.
                          Kevin Simpson: (916) 858-5100
                 or visit the web site at www.thermogenesis.com